A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Phase of Trial: Phase III
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Exemestane (Primary) ; Goserelin; Leuprorelin; Tamoxifen
- Indications Male breast cancer
- Focus Therapeutic Use
- Acronyms MALE
- 07 Jun 2017 Biomarkers information updated
- 09 Feb 2016 Planned End Date changed from 1 Mar 2015 to 1 Mar 2018 as reported by ClinicalTrials.gov.
- 09 Feb 2016 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2018 as reported by ClinicalTrials.gov.